ICON Continues Asia-Pacific Expansion with New Office Opening in Shanghai and Senior Appointments in the Region
ICON
today announced its ongoing expansion in Asia-Pacific. ICON has opened a new office in Shanghai, China, and is also relocating its Beijing operations to larger premises. In addition, ICON has announced the appointment Dr. Malcolm Burgess, to the position of Executive Vice President, Asia-Pacific, and Ms. Paula Mumby, Vice President, Operations, Asia-Pacific for ICON’s resourcing business unit, DOCS.
Dr. Malcolm Burgess joined ICON in 2002 and has held a variety of leadership positions within the company, including Chief Operating Officer, US Operations from 2006 – 2009. He has over 30 years’ experience within the pharmaceutical industry and prior to ICON worked with Novartis, Hoechst Marion Roussel and SmithKline Beecham.
Ms. Paula Mumby has over 18 years’ experience in the pharmaceutical, CRO, biotechnology and medical device industries in the UK and Asia Pacific and has more than 10 years’ resourcing experience. Prior to joining DOCS, Ms. Mumby was Vice President, Asia Pacific and Japan at i3 Pharma Resourcing and also held a clinical development role at CSL.
ICON has been operating in Asia-Pacific for over 10 years and currently employs over 900 staff in the region. The new office in Shanghai follows ICON’s announcement in June 2010 of a new laboratory facility, which opened in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD). The new laboratory is ICON’s third laboratory in Asia-Pacific, and offers 3,000 square feet of laboratory space and a comprehensive menu of testing services.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
